Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
A phase 2 trial of Palbociclib, Cetuximab and Fulvestrant in head and neck squamous cell carcinoma, run by Pfizer, active and no longer recruiting.
Overview
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies is a phase 2 interventional study registered as NCT05226871 by Pfizer, with 35 participants enrolled, started 2022-07-07 and due to reach its primary completion in 2029-12-31. Interventions recorded: Palbociclib, Cetuximab, Fulvestrant and Letrozole.
Similar pages
not linked directly; found by shared links- TrialDNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Shares Palbociclib, Fulvestrant and the tag pipeline.
- TrialSNV4818 in Participants With Advanced Solid Tumors
Shares Palbociclib, Fulvestrant and the tag pipeline.
- TrialVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
Shares Palbociclib, Pfizer (incl. Seagen) and the tag pipeline.
- TrialA Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
Shares Fulvestrant, Pfizer (incl. Seagen) and the tag pipeline.
- TrialCapivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Shares Palbociclib, Fulvestrant and the tag pipeline.
- TrialStudy of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Shares Palbociclib, Pfizer (incl. Seagen) and the tag pipeline.
- TrialPhII ICb With/Without Erbitux in MBC Pts
Shares Cetuximab, Pfizer (incl. Seagen) and the tag pipeline.
- TrialClinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
Shares Fulvestrant, Pfizer (incl. Seagen) and the tag pipeline.